Compare BridgeBio Pharma Inc (BBIO) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Duke Energy Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Duke Energy Corp trades at $123.25 (market cap $94.49B). The key difference: Duke Energy Corp is far larger — about 5.7× BridgeBio Pharma Inc's market cap, and Duke Energy Corp pays a 3.58% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DUK | |
|---|---|---|
Market Cap | $16.61B | $94.49B |
Sector | Health | Utilities |
52-Week High | $90.17 | $133.46 |
52-Week Low | $47.29 | $113.99 |
Enterprise Value | $18.16B | $187.00B |
Dividend Yield | — | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Duke Energy (DUK) trades at $124.85, up 0.77% in the last session, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, exceeding the $1.30 estimate, and maintains strong profitability with a net margin of 15.78%. Revenue growth is steady, reaching $32.24B in 2025, while analyst consensus is a Buy with a $136.17 price target. Recent news highlights equity offerings and regulatory agreements impacting capital plans.
The outlook for DUK is cautiously optimistic, supported by consistent earnings performance and dividend payments, but weighed by high debt levels and bearish technical indicators. Investment appeal lies in its stable utility model and growth in power demand, though risks include regulatory scrutiny and interest rate sensitivity. The stock offers value near current levels with upside to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
